European Molecular Biology Laboratory European Bioinformatics Institute.
Brief Bioinform. 2019 May 21;20(3):767-777. doi: 10.1093/bib/bbx141.
Recent advances in proteomics allow the accurate measurement of abundances for thousands of proteins and phosphoproteins from multiple samples in parallel. Therefore, for the first time, we have the opportunity to measure the proteomic profiles of thousands of patient samples or disease model cell lines in a systematic way, to identify the precise underlying molecular mechanism and discover personalized biomarkers, networks and treatments. Here, we review examples of successful use of proteomics and phosphoproteomics data sets in as well as their integration other omics data sets with the aim of precision medicine. We will discuss the bioinformatics challenges posed by the generation, analysis and integration of such large data sets and present potential reasons why proteomics profiling and biomarkers are not currently widely used in the clinical setting. We will finally discuss ways to contribute to the better use of proteomics data in precision medicine and the clinical setting.
蛋白质组学的最新进展使得我们能够同时平行地对数千种蛋白质和磷酸化蛋白质进行精确的丰度测量。因此，我们首次有机会系统地测量数千个患者样本或疾病模型细胞系的蛋白质组学图谱，以确定精确的潜在分子机制，并发现个性化的生物标志物、网络和治疗方法。在这里，我们回顾了蛋白质组学和磷酸化蛋白质组学数据集在精准医学中的成功应用实例，以及它们与其他组学数据集的整合。我们将讨论生成、分析和整合此类大型数据集所带来的生物信息学挑战，并提出蛋白质组学分析和生物标志物目前尚未广泛应用于临床的潜在原因。最后，我们将讨论如何促进更好地将蛋白质组学数据应用于精准医学和临床环境。
